DiscoverCME in Minutes: Education in Primary Care
CME in Minutes: Education in Primary Care
Claim Ownership

CME in Minutes: Education in Primary Care

Author: Answers in CME

Subscribed: 11Played: 15
Share
© 2022

Description

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
222 Episodes
Reverse
MeiLan Han, MD, MS / Eddie Needham, MD, FAAFP / Valerie Chang - COPD Primary Care Playbook: Boosting Diagnosis, Treatment, and Therapy Escalation for Optimal Disease Control

MeiLan Han, MD, MS / Eddie Needham, MD, FAAFP / Valerie Chang - COPD Primary Care Playbook: Boosting Diagnosis, Treatment, and Therapy Escalation for Optimal Disease Control

2025-10-1701:06:01

Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD.
Jerry P. Abraham, MD MPH CMQ / Chuck Vega, MD- Primary Care Immunization Showdown: What Would You Do in These Complex Vaccine Scenarios?

Jerry P. Abraham, MD MPH CMQ / Chuck Vega, MD- Primary Care Immunization Showdown: What Would You Do in These Complex Vaccine Scenarios?

2025-10-1501:02:17

Please visit answersincme.com/860/CME-25-198904-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease and family medicine discuss complex immunization needs of all patients, especially those with altered immunocompetence. Upon completion of this activity, participants should be better able to: Review how having altered immunocompetence affects response to vaccines; Apply the national guideline recommendations for immunization in individuals with altered immunocompetence; and Formulate effective communication strategies to enhance vaccine uptake in individuals with altered immunocompetence.
Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

2025-10-0321:30

Please visit answersincme.com/MPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myelodysplastic syndromes discusses strategies for the management of FLT3-mutated acute myeloid leukemia. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML); Recognize the clinical significance of the evidence for approved FLT3 inhibitors in the first-line treatment of newly diagnosed, FLT3-mutated AML; Formulate strategies to maximize the impact of FLT3 inhibitors in the management of patients with newly-diagnosed, FLT3-mutated AML.
Lisa Larkin, MD, FACP, MSCP, IF - Advancing Menopause Management: Integrating Neurokinin-Targeted Therapies for Vasomotor Symptoms

Lisa Larkin, MD, FACP, MSCP, IF - Advancing Menopause Management: Integrating Neurokinin-Targeted Therapies for Vasomotor Symptoms

2025-10-0115:56

Please visit answersincme.com/VYT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses the management of vasomotor symptoms (VMS) associated with menopause. Upon completion of this activity, participants should be better able to: Identify VMS as a consequence of menopause; Evaluate the efficacy and safety of new and emerging neurokinin (NK)-targeted therapies for VMS; Implement shared decision-making for optimal VMS treatment outcomes
Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach

2025-09-3019:38

Please visit answersincme.com/UDT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses primary chemoimmunotherapy regimens in advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Apply biomarker testing results to guide initial treatment decisions in advanced endometrial cancer; Select the optimal therapy for a given patient with endometrial cancer, based on the latest evidence; Design patient-centered, multidisciplinary care plans that support treatment continuity and patient survivorship.
Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

2025-09-3017:51

Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.
Alice YY Cheng, MD, FRCPC / Jill Trinacty, MD, FRCPC, ABOM / Bruce A. Perkins, MD, MPH - From Daily to Weekly: Advancing the Basal Insulin Landscape for Type 2 Diabetes

Alice YY Cheng, MD, FRCPC / Jill Trinacty, MD, FRCPC, ABOM / Bruce A. Perkins, MD, MPH - From Daily to Weekly: Advancing the Basal Insulin Landscape for Type 2 Diabetes

2025-09-3018:17

Please visit answersincme.com/AVD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, three experts in diabetes discuss approved and emerging once-weekly insulin analogs. Upon completion of this activity, participants should be better able to: Identify patients with T2D who may benefit from basal insulin therapy, including those suited for once-weekly formulations; Assess the clinical data of approved and emerging once-weekly basal insulin analogs; Evaluate opportunities and challenges associated with once-weekly basal insulin therapy.
Vlad Ratziu, MD, PhD - Bridging Disciplines to Advance Care in MASH: Exploring GLP-1 RAs for Obesity-Related Liver Disease

Vlad Ratziu, MD, PhD - Bridging Disciplines to Advance Care in MASH: Exploring GLP-1 RAs for Obesity-Related Liver Disease

2025-09-2419:38

Please visit answersincme.com/WTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hepatology and endocrinology discuss the impact of obesity on liver disease progression, current and emerging GLP-1 receptor agonist therapies, and strategies to optimize clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Upon completion of this activity, participants should be better able to: Identify how obesity impacts metabolic dysfunction–associated steatohepatitis (MASH) progression and liver health; Review current and emerging glucagon-like peptide-1 (GLP-1) receptor agonist (RA)–based therapies for the treatment of MASH; and Outline approaches to optimize patient outcomes in obesity-related liver disease.
Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach

Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach

2025-09-2401:03:32

Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.
Christine Franzese, MD / Eileen Wang, MD, MPH - From Case to Clinic: Personalizing the Use of Biologics in CRSwNP Care Plans

Christine Franzese, MD / Eileen Wang, MD, MPH - From Case to Clinic: Personalizing the Use of Biologics in CRSwNP Care Plans

2025-09-2201:06:53

Please visit answersincme.com/860/MED-RESP-03359-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, ENT and allergy experts present strategies for incorporating the latest biologic therapies for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) via case-based challenges. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Select appropriate biologic therapies for patients with CRSwNP based on patient-, disease-, and drug-related factors; Apply guideline recommendations for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP.
Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

2025-09-1055:02

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.
Tina Q. Tan, MD / Litjen (L.J) Tan, MS, PhD - Empowering Patients, Strengthening Immunity: Strategies to Increase Influenza Vaccination Across All Age Groups

Tina Q. Tan, MD / Litjen (L.J) Tan, MS, PhD - Empowering Patients, Strengthening Immunity: Strategies to Increase Influenza Vaccination Across All Age Groups

2025-09-0957:18

Please visit answersincme.com/860/95719487-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in vaccine-preventable diseases discuss the most up-to-date evidence-based recommendations for flu vaccination, as well as strategies to enhance uptake across all age groups. Upon completion of this activity, participants should be better able to: Discuss the therapeutic rationale for seasonal influenza vaccination across all age groups; Describe the clinical profiles of recommended influenza vaccines; and Outline practical strategies to enhance influenza vaccination uptake across all age groups.
Priya Vakharia, MD - The Long View in Neovascular Age-Related Macular Degeneration: Practical Insights on Long-Acting Anti-VEGF Treatment

Priya Vakharia, MD - The Long View in Neovascular Age-Related Macular Degeneration: Practical Insights on Long-Acting Anti-VEGF Treatment

2025-09-0318:05

Please visit answersincme.com/XWJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a retina expert discusses the role of long-acting anti–vascular endothelial growth factor (VEGF) therapy in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the rationale for long-acting anti-VEGF therapy in nAMD; Select the optimal long-acting anti-VEGF therapy for individual patients with nAMD; and Integrate practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy in patients with nAMD.
Scott Solomon, MD - Mapping the Future of Heart Failure Care: The Evolving Role of Nonsteroidal MRAs in the Treatment of Patients With Heart Failure and Mildly Reduced/Preserved Ejection Fraction

Scott Solomon, MD - Mapping the Future of Heart Failure Care: The Evolving Role of Nonsteroidal MRAs in the Treatment of Patients With Heart Failure and Mildly Reduced/Preserved Ejection Fraction

2025-09-0118:05

Please visit answersincme.com/QWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure. Upon completion of this activity, participants should be better able to: Identify the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure; Evaluate clinical implications of the latest data on nonsteroidal MRAs for the treatment of heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF), in the context of current standard-of-care; and Describe strategies to incorporate nonsteroidal MRAs into the treatment plans of patients with HFmrEF or HFpEF.
Jesus Berdeja, MD - Chartering New Frontiers in Myeloma Care: What Role May Novel CELMoDs Play in Early-Relapse Therapy?

Jesus Berdeja, MD - Chartering New Frontiers in Myeloma Care: What Role May Novel CELMoDs Play in Early-Relapse Therapy?

2025-08-1817:42

Please visit answersincme.com/NPK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma (MM) answers common questions about incorporating novel cereblon E3 ligase modulators (CELMoDs) in early-relapse therapy for patients with MM. Upon completion of this activity, participants should be better able to: Identify the rationale for incorporating novel CELMoDs in early-relapse therapy in patients with MM; Discuss the clinical impact of the latest data for emerging novel CELMoDs in the early-relapse setting for patients with MM; and Describe potential considerations for integrating novel CELMoDs in the treatment landscape of MM as they become available.
April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Next-Generation Treatments for Moderate-to-Severe Plaque Psoriasis: What's New in TYK2

April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Next-Generation Treatments for Moderate-to-Severe Plaque Psoriasis: What's New in TYK2

2025-08-0455:28

Please visit answersincme.com/JCY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the current and potential clinical impact of TYK2 inhibitors. Upon completion of this activity, participants should be better able to: Contrast the clinical implications of selective TYK2 inhibition versus pan-JAK inhibition in the treatment of moderate-to-severe plaque psoriasis; Interpret the clinical evidence for next-generation TYK2 inhibitors in patients with moderate-to-severe plaque psoriasis; and Integrate TYK2 inhibitors into clinical practice as they become available for patients with moderate-to-severe plaque psoriasis.
Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation

Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation

2025-07-3119:40

Please visit answersincme.com/HSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in urothelial cancer discusses biomarker testing for patients with locally advanced/metastatic urothelial cancer. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes with novel approved therapies in locally advanced/metastatic UC (LA/mUC); Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following the identification of actionable biomarkers.
Fernando Jose Martinez, MD, MS, Justin Oldham, MD, MS - Advancing Patient-Centered ILD Care: Post-Congress Insights on Antifibrotics, Treatment Innovations, and Multidisciplinary Approaches

Fernando Jose Martinez, MD, MS, Justin Oldham, MD, MS - Advancing Patient-Centered ILD Care: Post-Congress Insights on Antifibrotics, Treatment Innovations, and Multidisciplinary Approaches

2025-07-2901:01:12

Please visit answersincme.com/ZXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in interstitial lung disease (ILD) discuss the latest information, including post-congress insights, on advancing patient-centered ILD care with antifibrotics, treatment innovations, and multidisciplinary approaches. Upon completion of this activity, participants should be better able to: Assess recommended antifibrotic treatment for patients with ILDs; Review the rationale for novel therapy for fibrosing ILDs; and Outline multidisciplinary, patient-centered strategies to enhance care for individuals with ILDs.
Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World

Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World

2025-07-2828:17

Please visit answersincme.com/860/97851223-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the practical application of immunotherapy-based regimens for the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.
John Marshall, MD - Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors

John Marshall, MD - Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors

2025-07-1822:43

Please visit answersincme.com/KTK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancers discusses strategies for treatment of patients with colorectal cancer using tyrosine kinase inhibitors. Upon completion of this activity, participants should be better able to: Identify patients with metastatic colorectal cancer (mCRC) who are suitable for tyrosine kinase inhibitor (TKI) treatment; Outline practical, patient-centered strategies to maximize quality of life in patients receiving later-line TKI treatment for mCRC; and Review approaches to manage adverse events associated with later-line TKI treatment for mCRC.
loading
Comments 
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States